1. Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line.
- Author
-
Guidetti L, Castelli R, Zappia A, Ferrari FR, Giorgio C, Barocelli E, Pagliaro L, Vento F, Roti G, Scalvini L, Vacondio F, Rivara S, Mor M, Lodola A, and Tognolini M
- Subjects
- Humans, Cell Line, Tumor, Dose-Response Relationship, Drug, Molecular Docking Simulation, Molecular Structure, Structure-Activity Relationship, Hydrocarbons, Fluorinated chemical synthesis, Hydrocarbons, Fluorinated chemistry, Hydrocarbons, Fluorinated pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Drug Discovery, Drug Screening Assays, Antitumor, Glioblastoma drug therapy, Glioblastoma pathology, Glioblastoma metabolism, Indoles pharmacology, Indoles chemistry, Indoles chemical synthesis, Receptor, EphA2 antagonists & inhibitors, Receptor, EphA2 metabolism
- Abstract
In our continuing effort devoted at developing agents targeting the EphA2 receptor by means of protein-protein interaction (PPI) inhibitors, we report here the design and synthesis of a new class of l-β-homotryptophan conjugates of 3-β-hydroxy-Δ
5 -cholenic acid bearing a set of arylsulfonyl substituents at the indole nitrogen atom. An extensive structure-activity relationship (SAR) analysis indicates that the presence of a bulky lipophilic moiety at the indole nitrogen is fundamental for improving potency on the EphA2 receptor, while abrogating activity on the EphB1-EphB3 receptor subtypes. A rational exploration, guided by the combined application of an experimental design on σp and π physicochemical descriptors and docking simulations, led to the discovery of UniPR1454, a 1-(4-(trifluoromethyl)phenyl)sulfonyl derivative acting as potent and competitive EphA2 antagonist able to inhibit ephrin-A1 dependent signals and to reduce proliferation of glioblastoma (U251) cell line at micromolar concentration., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Massimiliano Tognolini reports financial support was provided by Italian Association for Cancer Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF